New antiangiogenic strategies for the treatment of proliferative synovitis

Area of Science:

• Rheumatology and Oncology
• Molecular Biology
• Pharmacology

Background:

• Proliferative synovitis, particularly rheumatoid arthritis (RA), involves inflammation and joint destruction driven by the rheumatoid pannus.
• The rheumatoid pannus requires new blood vessel growth (angiogenesis) for its sustained development and activity.
• Key mediators like VEGF, FGF, integrins, angiopoietins, prostaglandins, and MMPs, along with hypoxia, stimulate angiogenesis in inflamed synovium.

Purpose of the Study:

• To explore the potential of angiogenesis inhibition as a novel therapeutic strategy for proliferative synovitis, specifically rheumatoid arthritis (RA).
• To review existing and emerging drugs that target angiogenesis for the treatment of RA.

Main Methods:

• Review of scientific literature on angiogenesis mediators and inhibitors in the context of RA.
• Identification of drugs that inhibit angiogenesis and are under investigation for proliferative synovitis.
• Analysis of drugs with prior success in oncologic disorders now being evaluated for RA treatment.

Main Results:

• Several naturally-occurring angiogenesis inhibitors like angiostatin and endostatin have been identified.
• Multiple drugs, including paclitaxel, anti-integrin alpha(V)beta3 antibody (LM-609), TNP-470, PPI-2458, PTK-787, bevacizumab, and thalidomide, are being studied for their anti-angiogenic effects in RA.
• These drugs aim to reduce RA signs and symptoms by inhibiting the neovascularization essential for the rheumatoid pannus.

Conclusions:

• Angiogenesis inhibition represents a novel and promising therapeutic avenue for rheumatoid arthritis.
• Drugs developed for cancer treatment that inhibit angiogenesis show potential for managing proliferative synovitis.
• Further clinical evaluation of these anti-angiogenic agents is warranted for effective RA treatment.